Zhejiang Medicine (600216.SH) has announced a forecasted increase, expecting a net profit of 1.039-1.246 billion yuan in 2024, an increase of 141.83%-190.01% compared to the previous year.
Zhejiang Medicine (600216.SH) has issued an announcement, the company is expected to achieve a net profit attributable to the parent company in the year of 2024...
Zhejiang Medicine (600216.SH) issued an announcement, stating that the company is expected to achieve a net profit attributable to the owners of the parent company of 1.039 billion to 1.246 billion yuan in 2024. Compared with the same period last year, it will increase by 609.36 million to 816.36 million yuan, a year-on-year increase of 141.83% to 190.01%.
Related Articles
The battle of computing power is heating up: Google opens their strategy and the Meta ecosystem turns against them, hoping to break Nvidia's CUDA ecosystem monopoly.
Morgan Stanley: Expects CICC (03908) stock price to rise in the next 30 days with a target price of 28.9 Hong Kong dollars.
HK Stock Market Move | MEDBOT-B (02252) rose over 6% in morning trading. The company was recently included in the HKEX Tech 100 Index.
The battle of computing power is heating up: Google opens their strategy and the Meta ecosystem turns against them, hoping to break Nvidia's CUDA ecosystem monopoly.
Morgan Stanley: Expects CICC (03908) stock price to rise in the next 30 days with a target price of 28.9 Hong Kong dollars.
HK Stock Market Move | MEDBOT-B (02252) rose over 6% in morning trading. The company was recently included in the HKEX Tech 100 Index.
RECOMMEND
Super Central Bank Week Arrives! Japan Leads With A Rate Hike As Developed Economies End The Rate‑Cut Cycle, Will The Fed Cut Alone Next Year?
16/12/2025
What Guidance Does The Economic Work Conference Offer For Cross‑Year Market Direction?
16/12/2025
Trade Surplus Tops One Trillion USD: New Challenges For China’s Foreign Trade | Instant Commentary
16/12/2025
